JPMorgan Chase & Co. purchased a new stake in Nabriva Therapeutics PLC – (NASDAQ:NBRV) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 159,659 shares of the biotechnology company’s stock, valued at approximately $431,000.
Several other institutional investors also recently added to or reduced their stakes in NBRV. Dimensional Fund Advisors LP boosted its holdings in Nabriva Therapeutics by 207.6% during the second quarter. Dimensional Fund Advisors LP now owns 344,061 shares of the biotechnology company’s stock worth $1,197,000 after purchasing an additional 232,196 shares during the last quarter. Clear Harbor Asset Management LLC boosted its holdings in Nabriva Therapeutics by 1,195.7% during the third quarter. Clear Harbor Asset Management LLC now owns 212,500 shares of the biotechnology company’s stock worth $443,000 after purchasing an additional 196,100 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Nabriva Therapeutics by 4,353.6% during the second quarter. Bank of America Corp DE now owns 55,403 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 54,159 shares during the last quarter. Institutional investors own 4.76% of the company’s stock.
Several research analysts recently commented on NBRV shares. BidaskClub cut shares of Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 21st. ValuEngine upgraded shares of Nabriva Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Zacks Investment Research cut shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 10th. Finally, SunTrust Banks reduced their target price on shares of Nabriva Therapeutics to $11.00 and set a “buy” rating for the company in a report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Nabriva Therapeutics currently has a consensus rating of “Buy” and an average price target of $9.96.
Nabriva Therapeutics (NASDAQ:NBRV) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $3.27 million. Nabriva Therapeutics had a negative net margin of 1,064.19% and a negative return on equity of 87.03%. As a group, equities research analysts predict that Nabriva Therapeutics PLC – will post -1.97 earnings per share for the current fiscal year.
In other news, Director Charles A. Rowland, Jr. purchased 53,000 shares of the business’s stock in a transaction on Monday, December 24th. The stock was purchased at an average price of $1.31 per share, for a total transaction of $69,430.00. Following the completion of the purchase, the director now directly owns 53,000 shares in the company, valued at approximately $69,430. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.15% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “JPMorgan Chase & Co. Purchases Shares of 159,659 Nabriva Therapeutics PLC – (NBRV)” was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://dakotafinancialnews.com/2019/01/12/jpmorgan-chase-co-purchases-shares-of-159659-nabriva-therapeutics-plc-nbrv.html.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
See Also: What is a Call Option?
Want to see what other hedge funds are holding NBRV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nabriva Therapeutics PLC – (NASDAQ:NBRV).
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.